These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24909420)

  • 21. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adamantane resistance in circulating human influenza A viruses from Alberta, Canada (1970-2007).
    Pabbaraju K; Ho KC; Wong S; Shokoples S; Pang XL; Fonseca K; Fox JD
    Antiviral Res; 2008 Aug; 79(2):81-6. PubMed ID: 18258311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexistence of two adamantane binding sites in the influenza A M2 ion channel.
    Rosenberg MR; Casarotto MG
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13866-71. PubMed ID: 20643947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
    Ma C; Zhang J; Wang J
    Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance.
    Simonsen L; Viboud C; Grenfell BT; Dushoff J; Jennings L; Smit M; Macken C; Hata M; Gog J; Miller MA; Holmes EC
    Mol Biol Evol; 2007 Aug; 24(8):1811-20. PubMed ID: 17522084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.
    Williams JK; Tietze D; Wang J; Wu Y; DeGrado WF; Hong M
    J Am Chem Soc; 2013 Jul; 135(26):9885-97. PubMed ID: 23758317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to overcome resistance of influenza A viruses against adamantane derivatives.
    Scholtissek C; Quack G; Klenk HD; Webster RG
    Antiviral Res; 1998 Feb; 37(2):83-95. PubMed ID: 9588841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flu channel drug resistance: a tale of two sites.
    Pielak RM; Chou JJ
    Protein Cell; 2010 Mar; 1(3):246-58. PubMed ID: 21203971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation into adamantane-based M2 inhibitors with FB-QSAR.
    Wei H; Wang CH; Du QS; Meng J; Chou KC
    Med Chem; 2009 Jul; 5(4):305-17. PubMed ID: 19689387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adamantan derivatives capable of inhibiting the reproduction of a Rimantadine resistant strain of influenza A(H1N1)pdm09 virus (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).].
    Garaev TM; Odnovorov AI; Kirillova ES; Burtseva EI; Finogenova MP; Mukasheva EA; Grebennikova TV
    Vopr Virusol; 2020; 65(1):16-20. PubMed ID: 32496716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular and genetic analysis of influenza A viruses isolated in Russia, based on the neuraminidase and M2 protein gene sequence].
    Rotanov M; Grebennikova TV; Burtseva EI; Shevchenko ES
    Mol Gen Mikrobiol Virusol; 2008; (2):27-32. PubMed ID: 18488446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Put a cork in it: Plugging the M2 viral ion channel to sink influenza.
    Jalily PH; Duncan MC; Fedida D; Wang J; Tietjen I
    Antiviral Res; 2020 Jun; 178():104780. PubMed ID: 32229237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free energy calculations on the two drug binding sites in the M2 proton channel.
    Gu RX; Liu LA; Wei DQ; Du JG; Liu L; Liu H
    J Am Chem Soc; 2011 Jul; 133(28):10817-25. PubMed ID: 21711026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance characteristics of influenza to amino-adamantyls.
    Astrahan P; Arkin IT
    Biochim Biophys Acta; 2011 Feb; 1808(2):547-53. PubMed ID: 20599692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.
    Wang J; Ma C; Wang J; Jo H; Canturk B; Fiorin G; Pinto LH; Lamb RA; Klein ML; DeGrado WF
    J Med Chem; 2013 Apr; 56(7):2804-12. PubMed ID: 23437766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008.
    Jonges M; van der Lubben IM; Dijkstra F; Verhoef L; Koopmans M; Meijer A
    Antiviral Res; 2009 Sep; 83(3):290-7. PubMed ID: 19591877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.
    Li F; Ma C; Hu Y; Wang Y; Wang J
    ACS Infect Dis; 2016 Oct; 2(10):726-733. PubMed ID: 27657178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis by metadynamics simulation of binding pathway of influenza virus M2 channel blockers.
    Sakai Y; Kawaguchi A; Nagata K; Hirokawa T
    Microbiol Immunol; 2018 Jan; 62(1):34-43. PubMed ID: 29210473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure of the drug-resistant S31N influenza M2 proton channel.
    Thomaston JL; DeGrado WF
    Protein Sci; 2016 Aug; 25(8):1551-4. PubMed ID: 27082171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.